Trial NCT02340221

View at ClinicalTrials.gov 
Org. Study IDs: GO29058
Secondary IDs: 2014-003185-25

Last trial update was posted on 2022-07-12

MeSH Interventions

Fulvestrant

MeSH Conditions

Breast Neoplasms Recurrence

Other Conditions

Breast Cancer

Stopping Reasons

The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID